CHOSA Oncology Invites Investors to Key June Events
CHOSA Oncology is set to unveil significant advancements in precision oncology at upcoming investor events in June.
Sammanfattning
CHOSA Oncology is hosting investor events to discuss advancements in their precision oncology platform, featuring their proprietary Cisplatin-DRP® biomarker.
CHOSA Oncology AB, a leading force in precision oncology, has announced a series of investor events scheduled for June 2025. These events aim to engage current and potential investors by showcasing the company's latest advancements in precision medicine, particularly their proprietary biomarker, Cisplatin-DRP®.
The first event will be held at the Aktiespararna- Aktiedagarna in Stockholm on June 11, 2025, where CEO Peter Buhl Jensen will present. The second event is scheduled for June 18, 2025, at the Økonomisk Ugebrev’s 'Investor Konference' in Copenhagen, with a presentation by CCO Claus Frisenberg Pedersen.
CHOSA's Cisplatin-DRP® is a groundbreaking biomarker that identifies patients most likely to respond to platinum-based chemotherapies like cisplatin and carboplatin. This innovation is crucial as it allows for more personalized treatment plans, minimizing exposure to ineffective and potentially harmful therapies.
Recent clinical trials have reinforced the efficacy of the Cisplatin-DRP® in predicting patient response to carboplatin, expanding its potential applications. These promising results are poised to be a focal point at the investor events, highlighting CHOSA's commitment to enhancing cancer treatment outcomes.
In line with their strategic growth plans, CHOSA's Board has approved a Directed Issue to raise approximately SEK 3.4 million. This capital will support the company's ongoing research and development efforts, ensuring they remain at the forefront of oncology innovation.
From an investment perspective, CHOSA presents a compelling opportunity. With a robust pipeline, proven leadership, and a strong focus on precision medicine, the company is well-positioned for future growth. Investors may consider a 'buy' stance, given the potential for significant advancements in the oncology sector and CHOSA's strategic initiatives.
Källa
Sammanfattning
CHOSA Oncology is inviting current and potential investors to two upcoming presentations in June to discuss their precision oncology platform and efforts to raise capital. Their main focus is the Cisplatin-DRP®, a biomarker that identifies patients likely to respond to cisplatin or carboplatin treatments. These events will provide insights into their clinical progress and commercial plans. The presentations will take place in Stockholm on June 11 and in Copenhagen on June 18. CHOSA's Board has approved a Directed Issue to raise approximately SEK 3.4 million by issuing new shares and warrants. The subscription price is SEK 1.86 per unit. CHOSA's approach involves using platinum-based therapies, such as cisplatin and carboplatin, which are key in treating various cancers. They have a patented gene test that helps identify patients who will benefit from these treatments, reducing the risk of ineffective or toxic therapy. The test has shown promising results in predicting responses to these drugs in breast and lung cancer patients. CHOSA aims to further validate their Cisplatin-DRP tool and explore its potential in combination with immunotherapies. They plan to enter partnerships for their products, including LiPlaCis® and the DRP® predictor, which have shown effectiveness in improving treatment outcomes for cancer patients.
